Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LUM-201
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2025
Lead Product(s) : LUM-201
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Double Point Ventures
Deal Size : Undisclosed
Deal Type : Merger
Lumos Acquired by Double Point Ventures After Tender Offer Completion
Details : Lumos’ lead therapeutic candidate, LUM-201 (ibutamoren ), is a novel, oral growth hormone (GH) secretagogue, currently being evaluated in multiple Phase 2 in Pediatric Growth Hormone Deficiency.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Double Point Ventures
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Double Point Ventures
Deal Size : Undisclosed
Deal Type : Merger
Lumos Pharma to Go Private with Double Point Ventures At $4.25/Share
Details : Lumos’ lead therapeutic candidate, LUM-201 (ibutamoren ), is a novel, oral growth hormone (GH) secretagogue, currently being evaluated in multiple Phase 2 in Pediatric Growth Hormone Deficiency.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Double Point Ventures
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LUM-201 (ibutamoren mesylate), an oral growth hormone stimulating small molecule which increases growth hormone levels by mimicking the action of the hormone ghrelin and binding to one of the ghrelin receptors in the brain.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LUM-201
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 03, 2023
Lead Product(s) : LUM-201
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LUM-201 (ibutamoren mesylate), an oral growth hormone stimulating small molecule which increases growth hormone levels by mimicking the action of the hormone ghrelin and binding to one of the ghrelin receptors in the brain.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2023
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LUM-201, an oral growth hormone secretagogue, has a unique mechanism of action, targeting specific receptors on the pituitary and hypothalamus to stimulate the natural pulsatile secretion of growth hormone for moderate idiopathic PGHD patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LUM-201, an oral growth hormone stimulating small molecule demonstrate a favorable safety profile as data from both OraGrowtH trials to date show comparable safety and tolerability to the rhGH subjects in the trials.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumos Pharma intends to analyze these interim datasets separately and also perform a combined analysis to increase the number of subjects in the top two LUM-201 dose cohorts.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2022